366 related articles for article (PubMed ID: 25022596)
1. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda.
Jain V; Byonanebye DM; Amanyire G; Kwarisiima D; Black D; Kabami J; Chamie G; Clark TD; Rooney JF; Charlebois ED; Kamya MR; Havlir DV;
AIDS; 2014 Sep; 28(15):2241-9. PubMed ID: 25022596
[TBL] [Abstract][Full Text] [Related]
2. High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya.
Kwarisiima D; Kamya MR; Owaraganise A; Mwangwa F; Byonanebye DM; Ayieko J; Plenty A; Black D; Clark TD; Nzarubara B; Snyman K; Brown L; Bukusi E; Cohen CR; Geng EH; Charlebois ED; Ruel TD; Petersen ML; Havlir D; Jain V
J Int AIDS Soc; 2017 Jul; 20(Suppl 4):21673. PubMed ID: 28770596
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
Cohan D; Natureeba P; Koss CA; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Gandhi M; Clark TD; Nzarubara B; Achan J; Ruel T; Kamya MR; Havlir DV
AIDS; 2015 Jan; 29(2):183-91. PubMed ID: 25426808
[TBL] [Abstract][Full Text] [Related]
4. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda.
Jain V; Chang W; Byonanebye DM; Owaraganise A; Twinomuhwezi E; Amanyire G; Black D; Marseille E; Kamya MR; Havlir DV; Kahn JG
PLoS One; 2015; 10(12):e0143433. PubMed ID: 26632823
[TBL] [Abstract][Full Text] [Related]
5. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
[TBL] [Abstract][Full Text] [Related]
6. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
[TBL] [Abstract][Full Text] [Related]
7. Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial.
Thirumurthy H; Ndyabakira A; Marson K; Emperador D; Kamya M; Havlir D; Kwarisiima D; Chamie G
Lancet HIV; 2019 Mar; 6(3):e155-e163. PubMed ID: 30660594
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
10. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.
Koss CA; Natureeba P; Mwesigwa J; Cohan D; Nzarubara B; Bacchetti P; Horng H; Clark TD; Plenty A; Ruel TD; Achan J; Charlebois ED; Kamya MR; Havlir DV; Gandhi M
AIDS; 2015 Apr; 29(7):825-30. PubMed ID: 25985404
[TBL] [Abstract][Full Text] [Related]
11. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
[TBL] [Abstract][Full Text] [Related]
12. CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: An analysis of national laboratory based data.
Kufa T; Shubber Z; MacLeod W; Takuva S; Carmona S; Bor J; Gorgens M; Pillay Y; Puren A; Eaton JW; Fraser-Hurt N
PLoS One; 2019; 14(5):e0217742. PubMed ID: 31150489
[TBL] [Abstract][Full Text] [Related]
13. Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.
Krogstad P; Patel K; Karalius B; Hazra R; Abzug MJ; Oleske J; Seage GR; Williams PL; Borkowsky W; Wiznia A; Pinto J; Van Dyke RB;
AIDS; 2015 Mar; 29(6):683-93. PubMed ID: 25849832
[TBL] [Abstract][Full Text] [Related]
14. Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda.
Koss CA; Natureeba P; Kwarisiima D; Ogena M; Clark TD; Olwoch P; Cohan D; Okiring J; Charlebois ED; Kamya MR; Havlir DV
J Acquir Immune Defic Syndr; 2017 Mar; 74(3):279-284. PubMed ID: 27828878
[TBL] [Abstract][Full Text] [Related]
15. Is CD4 monitoring needed among ugandan clients achieving a virologic and immunologic response to treatment?
Reynolds SJ; Sempa JB; Kiragga AN; Newell K; Nakigozi G; Galiwango R; Gray R; Quinn TC; Serwadda D; Chang L
AIDS Patient Care STDS; 2014 Nov; 28(11):575-8. PubMed ID: 25290988
[TBL] [Abstract][Full Text] [Related]
16. ART adherence and viral suppression are high among most non-pregnant individuals with early-stage, asymptomatic HIV infection: an observational study from Uganda and South Africa.
Haberer JE; Bwana BM; Orrell C; Asiimwe S; Amanyire G; Musinguzi N; Siedner MJ; Matthews LT; Tsai AC; Katz IT; Bell K; Kembabazi A; Mugisha S; Kibirige V; Cross A; Kelly N; Hedt-Gauthier B; Bangsberg DR
J Int AIDS Soc; 2019 Feb; 22(2):e25232. PubMed ID: 30746898
[TBL] [Abstract][Full Text] [Related]
17. Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy.
Jose S; Quinn K; Hill T; Leen C; Walsh J; Hay P; Fisher M; Post F; Nelson M; Gompels M; Johnson M; Chadwick D; Gilson R; Sabin C; Fidler S;
AIDS; 2014 Jun; 28(9):1333-9. PubMed ID: 24583670
[TBL] [Abstract][Full Text] [Related]
18. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.
Mermin J; Ekwaru JP; Were W; Degerman R; Bunnell R; Kaharuza F; Downing R; Coutinho A; Solberg P; Alexander LN; Tappero J; Campbell J; Moore DM
BMJ; 2011 Nov; 343():d6792. PubMed ID: 22074711
[TBL] [Abstract][Full Text] [Related]
19. Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa.
Bor J; Fox MP; Rosen S; Venkataramani A; Tanser F; Pillay D; Bärnighausen T
PLoS Med; 2017 Nov; 14(11):e1002463. PubMed ID: 29182641
[TBL] [Abstract][Full Text] [Related]
20. Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.
O'Connor JL; Smith CJ; Lampe FC; Hill T; Gompels M; Hay P; Chadwick D; Fisher M; Ainsworth J; Gilson R; Mackie N; Anderson J; Orkin C; Nelson M; Kegg S; Leen C; Palfreeman A; Post F; Johnson M; Sabin CA; Phillips AN;
AIDS; 2014 Mar; 28(6):919-24. PubMed ID: 24335482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
